Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice

Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice

Immunotherapy focusing on reducing the amyloid-beta (Aβ) burden is a promising treatment strategy for Alzheimer’s disease (AD). Many clinical studies on AD immunotherapies have failed due to low safety and efficacy, calling for a highly potent AD vaccine which induces sufficient antibody titer while...

Full description

Bibliographic Details
Main Authors: Dong-qun Liu, Shuai Lu, Lun Zhang, Ya-ru Huang, Mei Ji, Xiao-ying Sun, Xiao-ge Liu, Rui-tian Liu
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Vaccines
Subjects:
Alzheimer’s disease
beta-amyloid
active immunotherapy
yeast
vaccine
Online Access:https://www.mdpi.com/2076-393X/8/3/351

Internet

https://www.mdpi.com/2076-393X/8/3/351

Similar Items